Literature DB >> 1665917

Peripheral opioid secretory pattern in anorexia nervosa.

F Brambilla1, E Ferrari, F Petraglia, F Facchinetti, M Catalano, A R Genazzani.   

Abstract

The peripheral secretion of endogenous opioids was studied in 10 women with restrictive anorexia nervosa and 10 age- and sex-matched healthy controls. The circadian rhythm of beta-endorphin (beta-EP) and beta-lipotropin (beta-LPH), and their responses to the administration of corticotropin releasing hormone (CRH, 1 micrograms/kg body weight, i.v.), clonidine (150 microgram, i.v.), domperidone (10 mg, i.v.), and 5-hydroxytryptophan (5-HTP, 200 mg, p.o.) were examined in patients and controls. The results revealed increased nocturnal secretion of beta-EP and diurnal-nocturnal secretion of beta-LPH with loss of circadian rhythmicity of both peptides, normal response to CRH stimulation, blunted response to clonidine and domperidine, and normal beta-EP and blunted beta-LPH response to 5-HTP stimulation. The data suggest a complex alteration of peripheral opioids and of central aminergic mechanisms that regulate proopiomelanocortin-derived peptide secretion and eating behavior.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665917     DOI: 10.1016/0165-1781(91)90081-y

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  3 in total

Review 1.  Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

Authors:  F Brambilla
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Ghrelin: central and peripheral implications in anorexia nervosa.

Authors:  Mathieu Méquinion; Fanny Langlet; Sara Zgheib; Suzanne Dickson; Bénédicte Dehouck; Christophe Chauveau; Odile Viltart
Journal:  Front Endocrinol (Lausanne)       Date:  2013-02-26       Impact factor: 5.555

Review 3.  Anorexia nervosa: a unified neurological perspective.

Authors:  Tasneem Fatema Hasan; Hunaid Hasan
Journal:  Int J Med Sci       Date:  2011-10-22       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.